ELICIO THERAPEUTICS INC

ELTXNASDAQ

🏆 #3299 by market capEarnings Aug 13US Equity

$3.03▼ $0.07 (−2.26%)

🌙 After hours$3.04▲ 0.33%Regular close · extended-hours price shown

1h—

24h▼ 2.3%

7d▼ 5.3%

14d▲ 5.6%

30d▼ 7.9%

1y▼ 68.2%

🏦Market Cap

$58M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $3.01 – $3.08
52-Week Range: $2.66 – $16.00
Volume: $4.68B
Avg Volume: $6.04B
Shares Outstanding: 19.1M
Next Earnings: Sep 24, 2026

Fundamentals Snapshot

Annual Revenue: $4M
Last Q Revenue: $1M
P/E Ratio: -1.3
P/S Ratio: 0.0x
EPS (TTM): $-2.21
Dividend Yield: 0.00%

Why Investors Own ELTX

✓High-growth profile — revenue up +6.9% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$4M▲ +9.8% YoY

Gross Margin (TTM)

27.0%▲ +4.0% YoY

Operating Income (TTM)

$585,678▲ +9.8% YoY

Free Cash Flow (TTM)

$306,784▲ +9.8% YoY

About ELICIO THERAPEUTICS INC

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

🦦